License and Acquisition Agreements - Regeneron License Agreement (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
License and Acquisition Agreements
Research and development		$ 26,057	$ 17,106	$ 76,408	$ 56,045
Uncured period which causes termination of the agreement, due to insolvency or bankruptcy or for material breach of the agreement by the other party that remains uncured	90 days
Notice period to terminate the agreement under payment-related breaches	30 days
Consecutive suspension of activities period for termination of agreement	12 months
Notice period to terminate the agreement	1 year
Notice period to terminate the agreement if products are having safety concerns	3 months
Commercial product inventory		28,680		28,680		$ 31,122
Regulatory milestone
License and Acquisition Agreements
Intangible asset - Regulatory milestone		20,000		20,000		20,000
Regeneron | License agreement
License and Acquisition Agreements
Profit sharing recognized		29,152	17,311	79,218	39,585
Regeneron | Clinical supply agreement
License and Acquisition Agreements
Research and development		0	$ 0	0	$ 0
Commercial product inventory		$ 23,468		$ 23,468		$ 31,122